Genprex (NASDAQ:GNPX) Trading Down 2.8% – Here’s Why

Genprex (NASDAQ:GNPX)’s share price traded down 2.8% on Monday . The company traded as low as $0.8306 and last traded at $0.8453. 378,736 shares were traded during mid-day trading, a decline of 71% from the average session volume of 1,289,422 shares. The stock had previously closed at $0.87.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Genprex Price Performance

The business has a 50 day moving average of $1.52 and a 200 day moving average of $2.60. The firm has a market capitalization of $8.81 million, a price-to-earnings ratio of -0.03 and a beta of -0.94.

Hedge Funds Weigh In On Genprex

Hedge funds have recently made changes to their positions in the business. Mayflower Financial Advisors LLC bought a new position in shares of Genprex during the 1st quarter worth about $36,000. Manchester Financial Inc. bought a new stake in Genprex in the first quarter valued at about $36,000. Finally, Susquehanna International Group LLP increased its stake in Genprex by 11.7% in the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after acquiring an additional 35,661 shares during the period. Institutional investors and hedge funds own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.